Matches in Nanopublications for { ?s ?p "[The anti-VEGF monoclonal antibody bevacizumab was approved in 2004 as a first-line treatment for metastatic colorectal cancer (CRC) in combination with chemotherapy and provided proof of principle for antiangiogenic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_assertion description "[The anti-VEGF monoclonal antibody bevacizumab was approved in 2004 as a first-line treatment for metastatic colorectal cancer (CRC) in combination with chemotherapy and provided proof of principle for antiangiogenic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_provenance.
- NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_assertion description "[The anti-VEGF monoclonal antibody bevacizumab was approved in 2004 as a first-line treatment for metastatic colorectal cancer (CRC) in combination with chemotherapy and provided proof of principle for antiangiogenic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_provenance.